




Figure 1**A. Outcross design:****B. Isogenic design:****C. Isogenic mapping partner:**

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Table S1 Sequencing of the B6-SNV lines.

Line	Raw (Gbp)	Mapped (Gbp)	Coverage (times)	N of all candidate SNVs*	N of line-specific candidate SNVs**
SNVb	27.40	23.83	7.94	9864	3246
SNVc	20.61	17.21	5.74	9028	2932
SNVe	14.64	12.24	4.08	7094	2051
SNVf	6.05	5.14	1.71	2925	1198
SNVg	28.38	24.25	8.08	6324	1225
SNVh	23.85	20.03	6.68	9559	2520

*There were 22911 sites overall: 13172 appeared in only 1 line, 3590 in 2, 2187 in 3, 2212 in 4, 1467 in 5, and 283 in all 6 lines.

**In addition, lines B6.SNVg and B6.SNVh, which are known to be related, share 792 candidate variants that are found in none of the other lines.

Table S2 The spectrum of distances between 13172 adjacent line-specific candidate variants.
 Note that 13172 SNVs on 120 chromosomes yield 13052 distances.

Distance between adjacent SNVs (bp)	N of SNVs	Cumulative total	Cumulative %
1	58	58	0.4
2	62	120	0.9
3	50	170	1.3
4	66	236	1.8
5	66	302	2.3
6	38	340	2.6
7	29	369	2.8
8	33	402	3.1
9	27	429	3.3
10	28	457	3.5
11	25	482	3.7
12	28	510	3.9
13	15	525	4.0
14	17	542	4.2
15	20	562	4.3
16	11	573	4.4
17	10	583	4.5
18	16	599	4.6
19	8	607	4.7
20	18	625	4.8
21	15	640	4.9
22	10	650	5.0
23	5	655	5.0
24	9	664	5.1
25	10	674	5.2
26-1000	683	1357	10.4
1001-10,000	970	2327	17.8
10001-100,000	1696	4023	30.8
100,001-1,000,000	5448	9471	72.6
1,000,001-45,000,000	3581	13052	100.0




Figure S1. Sample size requirements in a progeny test for various fold effects modifying the expected tumor count, both (A) without prescreening, assuming 1/100 gametes have a modifier with directional effect shown, and (B) with survival-based pre-screening such that ¼ of gametes have directional effect shown. Sample sizes are calculated such that a 5% FDR-controlled list of modified kindreds is non-empty with 95% probability. In all cases the non-modified tumor-count distribution is Negative Binomial, with mean 99.8 tumors and shape parameter 9.8, as estimated from control data. Modifiers are assumed to affect the mean (and thus the variance), but not the shape parameter. (Recall that a Negative Binomial distribution has mean μ and variance $\mu \cdot (1 + \mu / \text{shape})$). Calculations allow segregation of each mutant modifier within a carrier kindred and use a normal approximation for the distribution of average tumor count. We reckoned that a one-hit mutagenesis library will produce 1/50 gametes carrying some modifier, and that ½ of these may be in a specific direction, and this determined the rates used above. Without pre-screening, the burden of a tumor-count-based progeny test is especially high in terms of the number of kindreds required to be tested.





Figure S2 The candidate SNV sites that are line-specific or specific to only lines B6.SNVg and B6.SNVh.

